This whitepaper outlines the principles of TPD and PROTACs, introduces the D2B concept, and explores how a D2B approach can streamline the DMTA cycle in PROTAC discovery. We explore recent literature and real-world examples to illustrate gains in speed, efficiency, and sustainability, and highlight practical considerations for scientists interested in adopting D2B in their own programs.
Sponsored by
Concept Life Sciences
Concept Life Sciences is a UK-based drug discovery CRO, helping global pharma and biotech companies accelerate their drug candidate to clinic by offering integrated drug discovery programs.